Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

3,293 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Interferon β-1b and glatiramer acetate effects on permanent black hole evolution.
Filippi M, Rocca MA, Camesasca F, Cook S, O'Connor P, Arnason BG, Kappos L, Goodin D, Jeffery D, Hartung HP, Comi G, Wolinsky JS, Bogumil T, Pohl C, Beckmann K, Sandbrink R, Croze E, Brown C, Desimone TM, Arnold DL, Cutter G, Knappertz V. Filippi M, et al. Among authors: cook s. Neurology. 2011 Apr 5;76(14):1222-8. doi: 10.1212/WNL.0b013e3182143577. Neurology. 2011. PMID: 21464426 Free PMC article. Clinical Trial.
250 microg or 500 microg interferon beta-1b versus 20 mg glatiramer acetate in relapsing-remitting multiple sclerosis: a prospective, randomised, multicentre study.
O'Connor P, Filippi M, Arnason B, Comi G, Cook S, Goodin D, Hartung HP, Jeffery D, Kappos L, Boateng F, Filippov V, Groth M, Knappertz V, Kraus C, Sandbrink R, Pohl C, Bogumil T; BEYOND Study Group; O'Connor P, Filippi M, Arnason B, Cook S, Goodin D, Hartung HP, Kappos L, Jeffery D, Comi G. O'Connor P, et al. Among authors: cook s. Lancet Neurol. 2009 Oct;8(10):889-97. doi: 10.1016/S1474-4422(09)70226-1. Epub 2009 Sep 2. Lancet Neurol. 2009. PMID: 19729344 Clinical Trial.
Can the functional assessment of multiple sclerosis adapt to changing needs? A psychometric validation in patients with clinically isolated syndrome and early relapsing-remitting multiple sclerosis.
Acaster S, Swinburn P, Wang C, Stemper B, Beckmann K, Knappertz V, Pohl C, Sandbrink R, Gondek K, Edan G, Kappos L, Freedman M, Hartung HP, Arnason B, Comi G, Filippi M, Jeffery D, O'Connor P, Cook S, Lloyd AJ. Acaster S, et al. Among authors: cook s. Mult Scler. 2011 Dec;17(12):1504-13. doi: 10.1177/1352458511414039. Epub 2011 Jul 14. Mult Scler. 2011. PMID: 21757536
Integration of genetic risk factors into a clinical algorithm for multiple sclerosis susceptibility: a weighted genetic risk score.
De Jager PL, Chibnik LB, Cui J, Reischl J, Lehr S, Simon KC, Aubin C, Bauer D, Heubach JF, Sandbrink R, Tyblova M, Lelkova P; Steering committee of the BENEFIT study; Steering committee of the BEYOND study; Steering committee of the LTF study; Steering committee of the CCR1 study; Havrdova E, Pohl C, Horakova D, Ascherio A, Hafler DA, Karlson EW. De Jager PL, et al. Lancet Neurol. 2009 Dec;8(12):1111-9. doi: 10.1016/S1474-4422(09)70275-3. Epub 2009 Oct 29. Lancet Neurol. 2009. PMID: 19879194 Free PMC article.
Safety and tolerability of cladribine tablets in multiple sclerosis: the CLARITY (CLAdRIbine Tablets treating multiple sclerosis orallY) study.
Cook S, Vermersch P, Comi G, Giovannoni G, Rammohan K, Rieckmann P, Sørensen PS, Hamlett A, Miret M, Weiner J, Viglietta V, Musch B, Greenberg SJ; CLARITY Study Group. Cook S, et al. Mult Scler. 2011 May;17(5):578-93. doi: 10.1177/1352458510391344. Epub 2011 Jan 12. Mult Scler. 2011. PMID: 21228029 Clinical Trial.
A probiotic modulates the microbiome and immunity in multiple sclerosis.
Tankou SK, Regev K, Healy BC, Tjon E, Laghi L, Cox LM, Kivisäkk P, Pierre IV, Hrishikesh L, Gandhi R, Cook S, Glanz B, Stankiewicz J, Weiner HL. Tankou SK, et al. Among authors: cook s. Ann Neurol. 2018 Jun;83(6):1147-1161. doi: 10.1002/ana.25244. Epub 2018 Jun 8. Ann Neurol. 2018. PMID: 29679417 Free PMC article.
3,293 results